Adamis Pharma Shares Rise 16% After FDA Approves Zimhi for Opioid Overdose
By Chris Wack
Adamis Pharmaceuticals Corp. shares were up 16% in heavy trade
to $1.30 after the company said the U.S. Food and Drug
Administration has approved its Zimhi naloxone HCL injection 5
mg/0.5 mL product.
Volume for the stock was 122 million shares at 12:35 p.m. ET,
compared to its 65-day average volume of 3.2 million shares. The
stock has a public float of 147 million shares.
Adamis said Zimhi is a high-dose naloxone injection product
FDA-approved for use in the treatment of opioid overdose.
Naloxone is an opioid antagonist and is generally considered the
drug of choice for immediate administration for opioid overdose. It
works by blocking or reversing the effects of the opioid, including
extreme drowsiness, slowed breathing or loss of consciousness,
The company said it is preparing for the full commercial launch
of Zimhi in the first quarter of 2022.
Write to Chris Wack at email@example.com
(END) Dow Jones Newswires
October 18, 2021 12:53 ET (16:53 GMT)
Copyright (c) 2021 Dow Jones & Company, Inc.